Coagulation Profile Changes Due to Thromboprophylaxis and Platelets in Trauma Patients at High-Risk for Venous Thromboembolism

Autor:	Nicholas Namias, Carl I. Schulman, Juliet J. Ray, Kenneth G. Proctor, Casey J. Allen, Ronald J. Manning, Gerardo A. Guarch, Laura F. Teisch, Clark R. Murray, Alan S. Livingstone, Xiomara D. Ruiz, Jonathan P. Meizoso, Mena M. Hanna, Enrique Ginzburg
Rok vydání:	2015
Předmět:	medicine.medical_specialty medicine.diagnostic_test business.industry General Medicine Heparin Clot formation Gastroenterology Thromboelastography Clotting time Coagulation profile Internal medicine medicine Platelet business Prospective cohort study Venous thromboembolism medicine.drug
Zdroj:	The American Surgeon. 81:663-668
ISSN:	1555-9823 0003-1348
Popis:	We hypothesize there are coagulation profile changes associated both with initiation of thromboporphylaxis (TPX) and with change in platelet levels in trauma patients at high-risk for venous thromboembolism (VTE). A total of 1203 trauma intensive care unit patients were screened with a VTE risk assessment profile. In all, 302 high-risk patients (risk assessment profile score ≥ 10) were consented for weekly thromboelastography. TPX was initiated between initial and follow-up thromboelastography. Seventy-four patients were analyzed. Upon admission, 87 per cent were hypercoagulable, and 81 per cent remained hypercoagulable by Day 7 ( P = 0.504). TPX was initiated 3.4 ± 1.4 days after admission; 68 per cent received unfractionated heparin and 32 per cent received low-molecular-weight heparin. The VTE rate was 18 per cent, length of stay 38 (25–37) days, and mortality of 17.6 per cent. In all, 76 per cent had a rapid clotting time at admission versus 39 per cent at Day 7 ( P < 0.001); correcting from 7.75 (6.45–8.90) minutes to 10.45 (7.90–15.25) minutes ( P < 0.001). At admission, 41 per cent had an elevated maximum clot formation (MCF) and 85 per cent had at Day 7 ( P < 0.001); increasing from 61(55–65) mm to 75(69–80) mm ( P < 0.001). Platelets positively correlated with MCF at admission (r = 0.308, R2 = 0.095, P = 0.008) and at Day 7 (r = 0.516, R2 = 0.266, P < 0.001). Change in platelet levels correlated with change in MCF (r = 0.332, R2 = 0.110, P = 0.005). In conclusion, hypercoagulability persists despite the use of TPX. Although clotting time normalizes, MCF increases in correlation with platelet levels. As platelet function is a dominant contributor to sustained trauma-evoked hypercoagulability, antiplatelet therapy may be indicated in the management of severely injured trauma patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::49a1a3f2b10c5b7c0d6c590dfad81a9c https://doi.org/10.1177/000313481508100713 Zobrazit plný text záznamu